Wang et al. discovered that SNHG5 was downregulated in NSCLC tissues, and high SNHG5 expression may enhance the sensitivity of A549 cells to gefitinib by interacting with the miR377/CASP1 axis [63]. Here, SNHG5 is linked to non-small cell lung carcinoma.